- Dalpiciclib plus fulvestrant in HR+/HER2-advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trialZhang, P.; Zhang, Q. Y.; Hu, X.; Li, W.; Tong, Z.; Sun, T.; Teng, Y.; Wu, X.; Ouyang, Q.; Yan, X.; Cheng, J.; Liu, Q.; Feng, J.; Wang, X.; Xu, G.; Wu, F.; Xia, B.; Xu, B.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 2022-09-09 To 2022-09-13.被引 1
- Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional studyZhao, Yannan; Geng, Cuizhi; Zhang, Hongwei; Cai, Li; Yao, Herui; Lin, Ying; Liu, Jianxia; Yang, Jin; Zhang, Jin; Wang, Xiaojia; Li, Yafen; Pang, Danmei; Sun, Tao; Wang, Xi; Ma, Jie; Zang, Aimin; Xu, Zhengyang; Wang, Yongsheng; Wang, Chuan; Hu, XichunAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2-advanced breast cancer: A phase Ib study.Zhang, Qingyuan; Zhang, Pin; Yan, Min; Yan, Xi; Wang, Xian; Gu, Yuanting; Qu, Xiujuan; Li, Shaorong; Xu, Guoying; Yang, Wenhui; Zhu, Xiaoyu; Zhang, Xiaojing; Xu, BingheAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
会议论文
Capivasertib (C) plus fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2e advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort
2阅读
